Response and duration
| Response category . | Cohort 1, N = 45* . | |
|---|---|---|
| No. (%) . | Duration (mo) . | |
| CR | 8 (18%) | 3, 3, 6, 12, 13+, 17, 49+, 74 |
| PR | 9 (20%) | 2, 3, 3, 5, 6, 8, 9, 12, 23+ |
| SD | 5 (11%) | 3, 3, 6, 6, 12 |
| PD | 18 (40%) | |
| NE | 5 (11%) | |
| Response category . | Cohort 1, N = 45* . | |
|---|---|---|
| No. (%) . | Duration (mo) . | |
| CR | 8 (18%) | 3, 3, 6, 12, 13+, 17, 49+, 74 |
| PR | 9 (20%) | 2, 3, 3, 5, 6, 8, 9, 12, 23+ |
| SD | 5 (11%) | 3, 3, 6, 6, 12 |
| PD | 18 (40%) | |
| NE | 5 (11%) | |
Two patients were excluded from response assessment: one patient discovered to be ineligible for enrollment after receiving the first dose and one patient whose T-cell lymphoma was reclassified as DLBCL.